

Supplementary Material

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

Tomomi Sanomachi¹, Hitomi Sumiyoshi Okuma¹, Rui Kitadai¹, Asuka Kawachi¹, Shu Yazaki¹, Momoko Tokura¹, Motoko Arakaki¹, Ayumi Saito¹, Shosuke Kita¹, Kasumi Yamamoto¹, Aiko Maejima¹, Yuki Kojima¹, Tadaaki Nishikawa¹, Kazuki Sudo¹, Tatsunori Shimoi¹, Emi Noguchi¹, Yasuhiro Fujiwara¹, Hirokazu Sugino², Sho Shiino³, Akihiko Suto³, Masayuki Yoshida², Kan Yonemori¹

* **Correspondence:** Hitomi Sumiyoshi Okuma MD, PhD: hsumiyos@ncc.go.jp

1 Supplementary Tables

Supplementary Table 1. HER2 status of 42 cases. Two pathologists reviewed HER2 status using the ASCO/CAP2018 criteria. The agreement between the final HER2 status and medical records was 39/42 cases (92.9%). 10 cases were stained with CB11 and 32 cases with HercepTest II.

Patient number	At or before diagnosis (ASCO/CAP2007)	Pathologist 1 At diagnosis (ASCO/CAP2018)	Pathologist 2 At diagnosis (ASCO/CAP2018)	Consensus between pathologists 1 & 2
1	0	0	0	0
2	0	0	0	0
3	0	0	0	0
4	0	0	0	0
5	0	0	0	0
6	0	0	0	0
7	0	0	0	0

8	0	1+	0 or 1+	1+
9	0	0	0	0
10	0	0	0	0
11	0	0	0	0
12	0	0	0	0
13	1+	1+	1+	1+
14	0	0	0	0
15	0	0	0	0
16	0	0	0	0
17	0	0	0	0
18	0	0	0	0
19	0	0	0	0
20	0	0	0	0
21	0	0	0	0
22	0	0	0	0
23	0	0	0	0
24	0	0	0	0
25	0	0	0	0
26	0	0	0	0
27	0	0	0	0

28	0	0	0	0
29	0 (intraductal 1+)	0	0	0
30	1+	1+	1+	1+
31	1+	2+	2+	2+/ISH negative
32	0	0	0	0
33	1+	1+	1+	1+
34	1+	1+	1+	1+
35	1+	1+	1+	1+
36	1+	1+	1+	1+
37	1+	1+	1+	1+
38	1+	1+	1+	1+
39	0	0	0	0
40	0	0	0	0
41	1+	1+	1+	1+
42	1+	0	0	0